Sugi Predict

Sugi Predict / Compounds / SCHEMBL9950882

SCHEMBL9950882

SCHEMBL9950882

COC(=O)c1ncc(N)cn1

nearest known ligand 0.44

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ TSHR P16473 1/20 0.44
▸ CYP4F2 P78329 1/20 0.44
▸ CYP4A11 Q02928 1/20 0.44
▸ ALDH1A1 P00352 4/20 0.43
▸ KDM4E B2RXH2 4/20 0.43
▸ GAA P10253 2/20 0.43
▸ GLA P06280 1/20 0.43
▸ MAPK1 P28482 2/20 0.41
▸ F2 P00734 2/20 0.40
▸ CFTR P13569 1/20 0.39
▸ HSD17B10 Q99714 1/20 0.39
▸ NPSR1 Q6W5P4 1/20 0.39
▸ L3MBTL1 Q9Y468 1/20 0.39
▸ ATM Q13315 1/20 0.37
▸ OPRK1 P41145 1/20 0.37
▸ HPGD P15428 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14782142 0.80 MAPK1 (0.57) TSHRCYP4F2CYP4A11ALDH1A1KDM4E
SCHEMBL14127742 0.80 CYP4F2 (0.45) TSHRCYP4F2CYP4A11ALDH1A1KDM4E
SCHEMBL10382421 0.80 ATM (0.47) TSHRCYP4F2CYP4A11ALDH1A1KDM4E
SCHEMBL6873822 0.78 CYP4F2 (0.44) TSHRCYP4F2CYP4A11ALDH1A1KDM4E
SCHEMBL15264511 0.78 CA1 (0.47) CYP4F2CYP4A11ALDH1A1KDM4EGLA
SCHEMBL17014903 0.78 CYP4F2 (0.44) TSHRCYP4F2CYP4A11ALDH1A1KDM4E
SCHEMBL10328696 0.78 CYP4F2 (0.44) CYP4F2CYP4A11ALDH1A1KDM4EMAPK1
SCHEMBL26307858 0.78 CYP4F2 (0.44) TSHRCYP4F2CYP4A11ALDH1A1KDM4E
SCHEMBL658257 0.78 CYP4F2 (0.47) TSHRCYP4F2CYP4A11ALDH1A1KDM4E
SCHEMBL7159196 0.78 ALDH1A1 (0.37) ALDH1A1KDM4EGAAGLAHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12441703-B2 Carboxamides as modulators of sodium channels VERTEX PHARMACEUTICALS INCORPORATED (US) 2025-10-14 — — US disclosed
EP-4536356-A1 PYRIDINAMINE DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS Xenon Pharmaceuticals Inc. (CA) 2025-04-16 — — EP disclosed
US-20240400544-A1 N-(HYDROXYALKYL (HETERO)ARYL) TETRAHYDROFURAN CARBOXAMIDE ANALOGS AS MODULATORS OF SODIUM CHANNELS VERTEX PHARMACEUTICALS INCORPORATED (US) 2024-12-05 — — US disclosed
US-12060347-B2 Bicyclic heteroaryl substituted compounds BRISTOL-MYERS SQUIBB COMPANY (US) 2024-08-13 — — US disclosed
EP-4347584-A1 N-(HYDROXYALKYL (HETERO)ARYL) TETRAHYDROFURAN CARBOXAMIDE ANALOGS AS MODULATORS OF SODIUM CHANNELS Vertex Pharmaceuticals Incorporated (US) 2024-04-10 — — EP disclosed
EP-4347032-A1 SUBSTITUTED TETRAHYDROFURAN-2-CARBOXAMIDES AS MODULATORS OF SODIUM CHANNELS Vertex Pharmaceuticals Incorporated (US) 2024-04-10 — — EP disclosed
CN-117813302-A Substituted tetrahydrofuran-2-carboxamides as sodium channel modulators 沃泰克斯药物股份有限公司 2024-04-02 — — CN disclosed
CN-117794919-A N- (hydroxyalkyl (hetero) aryl) tetrahydrofurancarboxamide analogues as sodium channel modulators 沃泰克斯药物股份有限公司 2024-03-29 — — CN disclosed
US-20240101531-A1 PYRIDINAMINE DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS XENON PHARMACEUTICALS INC. (CA) 2024-03-28 — — US disclosed
WO-2023239729-A1 PYRIDINAMINE DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS XENON PHARMACEUTICALS INC. (CA) 2023-12-14 — — WO disclosed
US-8809342-B2 Glucagon receptor modulators PFIZER INC. (US) 2014-08-19 — — US disclosed
US-8809342-B2 Glucagon receptor modulators PFIZER INC. (US) 2014-08-19 — — US disclosed
US-8809342-B2 Glucagon receptor modulators PFIZER INC. (US) 2014-08-19 — — US disclosed
EP-2655331-A1 GLUCAGON RECEPTOR MODULATORS Pfizer Inc (US) 2013-10-30 — — EP disclosed
CN-103261165-A Glucagon receptor modulators PFIZER 2013-08-21 — — CN disclosed
US-20120165343-A1 Glucagon Receptor Modulators PFIZER INC. (US) 2012-06-28 — — US disclosed
WO-2012085745-A1 GLUCAGON RECEPTOR MODULATORS PFIZER INC. (US) 2012-06-28 — — WO disclosed
US-20120165343-A1 Glucagon Receptor Modulators PFIZER INC. (US) 2012-06-28 — — US disclosed
WO-2012085745-A1 GLUCAGON RECEPTOR MODULATORS PFIZER INC. (US) 2012-06-28 — — WO disclosed
US-20120165343-A1 Glucagon Receptor Modulators PFIZER INC. (US) 2012-06-28 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12060347-B2 Bicyclic heteroaryl substituted compounds F2, F2RL3, F12 TSHR 1191/4885CYP4F2 352/4885CYP4A11 62/4885
US-20240101531-A1 PYRIDINAMINE DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS KCNA1, KCNB1, KCNB2 TSHR 1321/4885CYP4F2 235/4885CYP4A11 568/4885
US-12441703-B2 Carboxamides as modulators of sodium channels TRPV1, SCN2A, SCN10A TSHR 3163/4885CYP4F2 3913/4885CYP4A11 4206/4885
US-20120165343-A1 Glucagon Receptor Modulators GLP1R, GCGR, GPR119 TSHR 39/4885CYP4F2 1487/4885CYP4A11 316/4885
US-20240400544-A1 N-(HYDROXYALKYL (HETERO)ARYL) TETRAHYDROFURAN CARBOXAMIDE ANALOGS AS MODULATORS OF SODIUM CHANNELS TRPV1, SCN1A, SCN2A TSHR 3395/4885CYP4F2 898/4885CYP4A11 1945/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.